Catalent initiated with an Equal Weight at Wells Fargo

Wells Fargo initiated coverage of Catalent with an Equal Weight rating and $43 price target. The firm sees long-term potential in Catalent’s biopharma outsourcing expertise in biologics, including CGT, but starts the name with an Equal Weight given potential continued impact from recent operational and financial forecasting challenges near-term.